VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) — InMed Prescribed drugs Inc. (“InMed” or the “Firm”) (Nasdaq: INM), a frontrunner within the analysis, improvement and manufacturing of uncommon cannabinoids, will report monetary outcomes on Friday, September 23, 2022 for the fiscal yr ended June 30, 2022.
Convention Name & Webcast:
Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Jap Time
Registration Hyperlink: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511
Webcast Hyperlink: https://edge.media-server.com/mmc/p/cnawzqhu
(Webcast replay accessible for 12 months)
To entry the decision by cellphone, please go to the registration hyperlink, and you’ll be supplied with dial in particulars. To keep away from delays, we today techs encourage individuals to register a day upfront or at a minimal quarter-hour earlier than the beginning of the decision.
The Firm’s full monetary statements and associated MD&A for the fiscal yr ended June 30, 2022, will probably be accessible at today techs noopener” title=”www.inmedpharma.com”>www.inmedpharma.com and at www.sedar.com.
About InMed: InMed Prescribed drugs is a world chief within today techs the analysis, improvement and manufacturing of uncommon cannabinoids, together with medical and preclinical applications focusing on the remedy of ailments with excessive unmet medical wants. We even have important know-how in growing proprietary manufacturing approaches to provide cannabinoids for varied market sectors. For extra data, go to www.inmedpharma.com and www.baymedica.com.
Vice President, Investor Relations and Company Communications
Cautionary Observe Relating to Ahead-Wanting Info:
This information launch comprises “forward-looking data” and “forward-looking statements” (collectively, “forward-looking data”) throughout the that means of relevant securities legal guidelines. Ahead-looking data relies on administration’s present expectations and beliefs and is topic to quite a today techs lot of dangers and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements. Ahead-looking data on this information launch consists of statements about: reporting monetary outcomes and enterprise updates for the fiscal yr ended June 30, 2022, on September 23, 2022; being a frontrunner within the analysis, improvement and manufacturing uncommon cannabinoids; medical and preclinical applications focusing on the remedy of ailments with excessive unmet medical wants; having important know-how in growing proprietary manufacturing approaches to provide cannabinoids for varied market sectors.
All forward-looking data herein is certified in its entirety by this cautionary assertion, and InMed disclaims any obligation to revise or replace any such forward-looking data or to publicly announce the results of any revisions to any of the forward-looking data contained herein to mirror future outcomes, occasions or developments, besides as required by regulation.